



The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value for both companies

Hamlet BioPharma AB ("Hamlet BioPharma" or the "Company"), an innovative pharmaceutical company that develops new therapies against cancer and infections, announces that the Company's board of directors will send out notice to an extraordinary general meeting to propose approval of a licensing agreement (the "License Agreement") between Hamlet BioPharma and major shareholder Linnane Pharma AB ("Linnane Pharma"). The licensing agreement means that Hamlet BioPharma licenses supplementary patent rights to Linnane Pharma regarding the substance Bamlet and enables Linnane Pharma and Hamlet BioPharma to jointly commercialize Bamlet and share future results. In short, the licensing agreement means that Hamlet BioPharma continuously up to and including the year 2044 will receive royalty of 25 percent of Linnane Pharma's future revenues from sales of products and other revenues such as license fees based on Bamlet. The licensing agreement is to be considered a related party transaction and requires approval at an extraordinary general meeting. Notice of the extraordinary general meeting will be published through a separate press release.

Background and motive for the License Agreement

The background to the board's proposal to enter into the Licensing Agreement is that Linnane Pharma, which drives the development of Bamlet, has made discoveries that open completely new business areas for the

commercialization of Bamlet in metabolism, an area that Hamlet BioPharma does not currently focus on. Linnane Pharma owns patents related to Bamlet, which protect the new discoveries. Hamlet BioPharma owns supplementary patents. The Licensing Agreement thus enables the commercialization of products based on Bamlet. The license according to the Licensing Agreement refers only to Bamlet.

Metabolism can be explained as the body's chemical processes for converting food and drink into energy. Linnane Pharma has shown in recent studies that Bamlet directly affects metabolism. In models, inhibition of obesity and type II diabetes is observed when Bamlet is added to the drinking water. New patents in Linnane Pharma protect the use of Bamlet to regulate metabolism. The results are being prepared for publication.

Licensing agreement between Hamlet BioPharma and Linnane Pharma

The Licensing agreement enables Linnane Pharma to commercialize products based on Bamlet, with the help of the supplementary patents which are licensed from Hamlet BioPharma. In brief, through the licensing agreement Hamlet BioPharma will continuously receive a royalty payment from Linnane Pharma of 25 percent of future revenues from the sale of products and other revenues such as license fees based on Bamlet. Linnane Pharma's obligation to pay royalty compensation to Hamlet BioPharma applies according to the Licensing Agreement until and including the time when Linnane Pharma's patent regarding Bamlet expires, which is in 2044.

Notice to extraordinary general meeting

The licensing agreement is to be considered a related party transaction as Linnane Pharma is a major shareholder in the Company, meaning that the Licensing Agreement must be submitted to a general shareholder's meeting for approval. Notice of the extraordinary general meeting for approval of the Licensing Agreement will be published through a separate press release. Hamlet BioPharma's chairman of the board Catharina Svanborg, majority shareholder in Linnane Pharma, has not participated in the board's treatment of or proposals for decisions at the extraordinary general meeting.

Invitation to investor meeting

Hamlet BioPharma invites investors and media for presentation of the proposal on 21 February 2025 at 12 before the extraordinary general meeting.

<http://hamletbiopharma.com/series-of-digital-events/>

For more information contact:

Catharina Svanborg

CEO

Telephone: +46-709 42 65 49

E-mail: catharina.svanborg@hamletbiopharma.com

Magnus Nylén

Acting Chairman of the Board
Phone: +46 705 75 97 92
E-mail: magnus.nylen@partnerfk.se